Study wrapper · #612
One dose of oral hexarelin protects chronic cardiac function after myocardial infarction.
Editor's note
In a mouse model of myocardial infarction, researchers reported that a single oral dose of hexarelin, given 30 minutes after coronary ligation, was associated with better-preserved chronic cardiac function, higher ejection fraction and fractional shortening, and lower lung-congestion indices, compared with vehicle, although 14-day mortality did not differ. Hexarelin also lowered plasma epinephrine and dopamine and shifted autonomic balance toward parasympathetic tone. The notable feature is the oral, single-dose route, which is unusual for a peptide and of practical interest. Caveats: a single acute rodent model, modest numbers, and no mortality benefit. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
Researchers studied hexarelin, a lab-made peptide, in mice that had a heart attack created by tying off a coronary artery. Unusually, hexarelin was given as a single dose by mouth (oral gavage) 30 minutes after the injury. Over the following weeks, mice given hexarelin had better heart pumping function and less lung congestion than untreated mice, though the number of animals that survived the first 14 days was similar in both groups. Hexarelin also lowered stress hormones in the blood and shifted the nervous system toward its calming branch. The interesting point is that even a single oral dose showed lasting effects. The abstract reports no adverse events. These are preclinical findings in mice; human studies would be needed before drawing conclusions.